Improving treatment outcomes for children with acute lymphoblastic leukemia using new targeted therapies.
Pediatric acute lymphoblastic leukemia: Improving outcomes through incorporation of novel targeted therapies into treatment for relapsed and newly diagnosed disease
This study is looking to improve treatment for kids and young adults with acute lymphoblastic leukemia by testing new therapies to see how well they work and who might benefit the most from them.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project ID | NIH-10849945 on NIH RePORTER |
What this research studies
This research focuses on enhancing the treatment of pediatric acute lymphoblastic leukemia (ALL) by integrating novel targeted therapies into the care of children, adolescents, and young adults. The approach involves conducting clinical trials through the National Clinical Trials Network, specifically the Children’s Oncology Group, to evaluate the effectiveness of new therapies for both newly diagnosed and relapsed cases. The research aims to better understand the toxicities associated with these therapies and to identify patients who may benefit the most based on their individual clinical and genetic profiles.
Who could benefit from this research
Good fit: Ideal candidates for this research include children and young adults diagnosed with acute lymphoblastic leukemia, particularly those with high-risk or relapsed disease.
Not a fit: Patients with other types of leukemia or those who are not within the pediatric age range may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved survival rates and reduced side effects for children suffering from acute lymphoblastic leukemia.
How similar studies have performed: Previous research has shown promising results with similar targeted therapies in treating acute lymphoblastic leukemia, indicating a potential for success in this novel approach.
Where this research is happening
Aurora, UNITED STATES
- University of Colorado Denver — Aurora, United States (Active)
Researchers
- Principal investigator: O'brien, Maureen Megan — University of Colorado Denver
- Study coordinator: O'brien, Maureen Megan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.